UniQure halves research, lays off 20% while CSO departs in major revamp
US and Dutch gene therapy maker uniQure will undergo a broad overhaul that includes laying off 20% of its workforce, the departure of its chief scientific officer and a more than 50% slashing of research and tech investment.
The moves come as gene therapy companies look for a way forward in the tough financing environment and as others seek exits. The trans-Atlantic biotech expects the pruning to save it $180 million over the next three years and take runway into the second quarter of 2027. UniQure said 114 positions will be eliminated.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.